Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

How zinc deficiency could worsen heart inflammation and what that means for patients

1

Mar 2026

How zinc deficiency could worsen heart inflammation and what that means for patients

This review examines how zinc regulates inflammatory and redox signaling pathways involved in myocarditis and pericarditis, highlighting mechanisms such as NF-κB inhibition and the redox zinc switch. The authors conclude that maintaining optimal zinc status may support cardiovascular resilience, while emphasizing that clinical translation requires further targeted trials.

Higher tyrosine levels linked to shorter lifespan in major UK Biobank analysis

1

Mar 2026

Higher tyrosine levels linked to shorter lifespan in major UK Biobank analysis

Researchers analyzed over 272,000 UK Biobank participants and used Mendelian randomization to investigate whether circulating phenylalanine and tyrosine influence lifespan. Genetically predicted higher tyrosine levels were linked to shorter lifespan, particularly in men, while phenylalanine showed no independent effect after adjustment.

Study maps how NF-κB regulates gene expression in cells

27

Feb 2026

Study maps how NF-κB regulates gene expression in cells

To further the quantitative understanding of cellular decision making, Dr. Gregory Reeves and his team in the chemical engineering department have worked to interpret how a transcription factor dictates the alteration of gene expression in cells.

NIH grant funds evaluation of expanded Medicare Advantage benefits

27

Feb 2026

NIH grant funds evaluation of expanded Medicare Advantage benefits

Today, more than half of older Americans receive their Medicare coverage through private Medicare Advantage plans. In 2020, that program made a sweeping policy shift, allowing those plans to offer supplemental benefits beyond traditional medical care, including groceries, meal deliveries, utilities, transportation, pest control, and air filters.

NIH’s continued investment fuels TMJ pain research

27

Feb 2026

NIH’s continued investment fuels TMJ pain research

Chronic pain is one of the most common health conditions worldwide. Back pain is the most frequently reported type, followed closely by head and face pain linked to the jaw joint, in the form of temporomandibular joint (TMJ) disorder.

Expanded Seq-Scope method boosts gene-mapping resolution within tissues

27

Feb 2026

Expanded Seq-Scope method boosts gene-mapping resolution within tissues

In 2021, a technology developed at University of Michigan, called Seq-Scope, revolutionized the ability to map gene activity within intact tissue at microscopic resolution, enabling researchers to measure all expressed mRNA molecules and determine precisely where they are located within the tissue, using an Illumina sequencer machine.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.